CSIMarket
 
Repare Therapeutics Inc   (RPTX)
Other Ticker:  
 
 
Price: $5.1700 $-0.12 -2.268%
Day's High: $5.33 Week Perf: -1.52 %
Day's Low: $ 5.11 30 Day Perf: -25.61 %
Volume (M): 46 52 Wk High: $ 13.85
Volume (M$): $ 236 52 Wk Avg: $8.33
Open: $5.28 52 Wk Low: $3.08



 Market Capitalization (Millions $) 218
 Shares Outstanding (Millions) 42
 Employees 124
 Revenues (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) -97
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 2

Repare Therapeutics Inc
Repare Therapeutics Inc. is a biotech company that focuses on the development of innovative precision cancer therapies using its proprietary SNIPRx platform. The company's platform uses synthetic lethality, a mechanism where targeting two genes would result in cell death, to identify novel and selective targets for the treatment of cancer.

Repare's technology works by screening synthetic lethality pairs in a large library of cancer cells to identify targets that are crucial for cancer cell survival. The company then develops small molecule drug candidates that selectively target these vulnerabilities without harming healthy cells.

Repare's pipeline includes four preclinical programs and one clinical program, RP-3500, which is a potential first-in-class oral small molecule targeted therapy that inhibits DNA-PK, a kinase that plays a critical role in DNA damage response and repair pathways that are essential for cancer cell survival. RP-3500 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.

Additionally, Repare has collaborations with industry leaders like Bristol Myers Squibb and Vertex Pharmaceuticals to develop innovative cancer therapies using its SNIPRx platform.

Apart from its novel technology, Repare also has a robust intellectual property portfolio, comprising more than 50 patent applications with worldwide coverage.

The company's leadership team comprises world-renowned scientists with extensive experience in genomic medicine, synthetic lethality, and drug discovery, including CEO Lloyd M. Segal, Chief Medical Officer Dr. Steve Murray, and Chief Scientific Officer Dr. Michael Zinda.

Based in Montreal, Canada, Repare is backed by leading investors like Versant Ventures, MPM Capital, and Orbimed Advisors, among others. The company's vision is to become a leader in precision oncology by developing groundbreaking cancer treatments that help patients live longer and healthier lives.


   Company Address: 7171 Frederick-Banting St-Laurent 0 QC
   Company Phone Number: 412-7018   Stock Exchange / Ticker: NASDAQ RPTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Repare Therapeutics Inc

Repare Therapeutics Inc. Struggles as Top-Line Plummets by -98.082% in Fiscal Q3 2023

epare Therapeutics Inc, a leading biotechnology company specializing in precision oncology, recently reported its fiscal interval ending September 30, 2023, which painted a bleak picture for the company's financial health. Revenue plummeted by a staggering -98.082% to $2.16 million, compared to the same reporting period the prior year. Additionally, the company's shortfall per share increased to $-0.45 from the previous year's $-0.28. With these alarming figures, Repare Therapeutics Inc is facing significant challenges that require immediate attention.
Dismal Fiscal Third Quarter Results:
Repare Therapeutics Inc's fiscal third quarter showed a net deficit of $-18.879 million, a dramatic shift from the bottom line of $75.461 million achieved during the same reporting period the previous year. This downturn in earnings further highlights the company's struggle to maintain financial stability. Unless addressed effectively, Repare Therapeutics Inc may face severe consequences that could impact its future growth prospects.

Repare Therapeutics Inc

Repare Therapeutics Inc (RPTX) Shines Bright with Remarkable Financial Results in Q2 2023

Repare Therapeutics Inc (RPTX) is a biotechnology company that specializes in developing innovative precision oncology drugs. The company recently reported its financial results for the April to June 30, 2023 period, showing significant improvements compared to the previous year.
During this period, RPTX managed to decrease its loss per share from $0.91 to $0.28, indicating a positive trend in the company's financial performance. Additionally, the company reported an improvement in its income per share, with a decrease from $0.83 to $0.

Repare Therapeutics Inc

Repare Therapeutics Inc Boasts Impressive Revenue of $5.678 Million in Q1 2023 Earnings Season2.

The stock market is a ground for investors, traders and analysts to explore the ever-expanding world of finance. In the midst of the bustling activity, there are a few companies that have managed to make the headlines, and one such company that is catching the eye of both seasoned and novice investors is Repare Therapeutics Inc.
The company has had a fruitful year with $5.678 million in revenue in the first quarter of 2023, showcasing its strong foothold in the market. However, the first quarter of 2023 wasn't all smooth-sailing for Repare Therapeutics Inc, as they experienced a net shortfall of $-34.941 million which was bigger than the previous year. Despite this, there is good news on the horizon because, according to recent financial reports, Repare Therapeutics Inc is expected to release their next financial report on August 03, 2023.
Repare Therapeutics Inc is a pioneer in the field of cancer treatments and has brought some of the most promising innovations to the forefront. Their focus on developing targeted and personalized therapies for cancer patients is gradually gaining traction in the oncology community, and with their promising early-stage clinical trials, the future looks bright for this innovative company.
So, for investors who are bullish on Repare Therapeutics Inc, the upcoming financial report on August 03, 2023, is something to look forward to. The past few years have been a roller-coaster ride for the company and its investors, but with the strong revenue growth and the expected release of their financial reports, there is much reason to believe that Repare Therapeutics Inc is destined for greatness.






 

Repare Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com